TBI and melphalan followed by allogeneic hematopoietic SCT in children with advanced hematological malignancies (original) (raw)

References

  1. Davies SM, Wagner JE, Shu XO, Blazar BR, Katsanis E, Orchard PJ et al. Unrelated donor bone marrow transplantation for children with acute leukemia. J Clin Oncol 1997; 15: 557–565.
    Article CAS PubMed Google Scholar
  2. Woolfrey AE, Anasetti C, Storer B, Doney K, Milner LA, Sievers EL et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood 2002; 99: 2002–2008.
    Article CAS PubMed Google Scholar
  3. Worth LL, Tran H, Petropoulos D, Culbert SC, Mullen CA, Roberts WM et al. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide. Bone Marrow Transplant 1999; 24: 947–952.
    Article CAS PubMed Google Scholar
  4. Duerst RE, Horan JT, Liesveld JL, Abboud CN, Zwetsch LM, Senf ES et al. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide. Bone Marrow Transplant 2000; 25: 489–494.
    Article CAS PubMed Google Scholar
  5. Cole CH, Pritchard S, Rogers PCJ, Davis JE, Phillips G, Chan KW . Intensive conditioning regimen for bone marrow transplantation in children with high-risk haematological malignancies. Med Pediatr Oncol 1994; 23: 464–469.
    Article CAS PubMed Google Scholar
  6. Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA et al. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant 2000; 26: 463–470.
    Article CAS PubMed Google Scholar
  7. de Lima M, van Besien K, Gajewski J, Khouri I, Andersson B, Korbling M et al. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. Bone Marrow Transplant 2000; 26: 333–338.
    Article CAS PubMed Google Scholar
  8. Matsuyama T, Kojima S, Kato K . Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen. Bone Marrow Transplant 1998; 22: 21–26.
    Article CAS PubMed Google Scholar
  9. Small TN, Young JW, Castro-Malaspina H, Prockop S, Wilton A, Heller G et al. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. Biol Blood Marrow Transplant 2007; 13: 235–244.
    Article CAS PubMed Google Scholar
  10. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631–637.
    Article CAS PubMed Google Scholar
  11. Bordigoni P, Esperou H, Souillet G, Pico J, Michel G, Lacour B et al. Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukemia after relapse while receiving chemotherapy: a Société Française de Greffe de Moelle study. Br J Hematol 1998; 102: 656–665.
    Article CAS Google Scholar
  12. Murata M, Nishida T, Haneda M, Kanie T, Taji H, Iida H et al. A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haematopoietic stem cell transplantation. Br J Hematol 1999; 105: 799–802.
    Article CAS Google Scholar
  13. Petropoulos D, Worth LL, Mullen CA, Madden R, Mahajan A, Choroszy M et al. Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematological malignancies. Bone Marrow Transplant 2006; 37: 463–467.
    Article CAS PubMed Google Scholar
  14. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009; 27: 377–384.
    Article PubMed Google Scholar
  15. Gaynon PS, Qu RP, Chappell RJ, Willoughby MLN, Tubergen DG, Steinherz PG et al. Survival after relapse in childhood acute lymphoblastic leukemia. Cancer 1998; 82: 1387–1395.
    Article CAS PubMed Google Scholar
  16. Aladjidi N, Auvrignon A, Leblanc T, Perel Y, Bénard A, Bordigoni P et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucémie Aiquë Myéloïde Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol 2003; 21: 4377–4385.
    Article CAS PubMed Google Scholar
  17. Nemecek ER, Gooley TA, Woolfrey AE, Carpenter PA, Matthews DC, Sanders JE . Outcome of allogeneic bone marrow transplantation for children with advanced acute myeloid leukemia. Bone Marrow Transplant 2004; 34: 799–806.
    Article CAS PubMed PubMed Central Google Scholar
  18. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.
    Article CAS PubMed Google Scholar
  19. Przepiorka D, Weisdorf D, Martin P, Klingemann H-G, Beatty P, Hows J et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.
    CAS PubMed Google Scholar
  20. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.
    Article CAS PubMed Google Scholar
  21. Boulad F, Steinherz P, Reyes B, Heller G, Gillio AP, Small TN et al. Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study. J Clin Oncol 1999; 17: 197–207.
    Article CAS PubMed Google Scholar
  22. Eapen M, Raetz E, Zhang MJ, Muehlenbein C, Devidas M, Abshire T et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood 2006; 107: 4961–4967.
    Article CAS PubMed PubMed Central Google Scholar
  23. Schroeder H, Gustafsson G, Saarinen-Pihkala UM, Glomstein A, Jonmundsson G, Nysom K et al. Allogeneic bone marrow transplantation in second remission of childhood acute lymphoblastic leukemia: a population-based case control study from the Nordic countries. Bone Marrow Transplant 1999; 23: 555–560.
    Article CAS PubMed Google Scholar
  24. Borgmann A, von Stackelberg A, Hartmann R, Ebell W, Klingebiel T, Peters C et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood 2003; 101: 3835–3839.
    Article CAS PubMed Google Scholar
  25. Anasetti C, Petersdorf EW, Martin PJ, Woolfrey A, Hansen JA . Improving availability and safety of unrelated donor transplants. Curr Opin Oncol 2000; 12: 121–126.
    Article CAS PubMed Google Scholar
  26. Lee SJ, Vogelsang G, Flowers MED . Chronic graft-versus-host disease. Biol Blood Marrow transplant 2003; 9: 215–233.
    Article CAS PubMed Google Scholar

Download references